Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Operating Leases: 2019-2024

Historic Operating Leases for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $16.9 million.

  • Keros Therapeutics' Operating Leases fell 21.65% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year decrease of 21.65%. This contributed to the annual value of $16.9 million for FY2024, which is 25.63% up from last year.
  • Latest data reveals that Keros Therapeutics reported Operating Leases of $16.9 million as of FY2024, which was up 25.63% from $13.4 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Operating Leases registered a high of $16.9 million during FY2024, and its lowest value of $231,000 during FY2021.
  • In the last 3 years, Keros Therapeutics' Operating Leases had a median value of $13.4 million in 2023 and averaged $14.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 51.47% in 2021, then spiked by 5,484.42% in 2022.
  • Over the past 5 years, Keros Therapeutics' Operating Leases (Yearly) stood at $476,000 in 2020, then plummeted by 51.47% to $231,000 in 2021, then soared by 5,484.42% to $12.9 million in 2022, then increased by 4.18% to $13.4 million in 2023, then grew by 25.63% to $16.9 million in 2024.